RU2005116678A - Композиции оксибутинина и способы чрескожной терапии оксибутинином - Google Patents

Композиции оксибутинина и способы чрескожной терапии оксибутинином Download PDF

Info

Publication number
RU2005116678A
RU2005116678A RU2005116678/15A RU2005116678A RU2005116678A RU 2005116678 A RU2005116678 A RU 2005116678A RU 2005116678/15 A RU2005116678/15 A RU 2005116678/15A RU 2005116678 A RU2005116678 A RU 2005116678A RU 2005116678 A RU2005116678 A RU 2005116678A
Authority
RU
Russia
Prior art keywords
oxybutynin
preparation
gel preparation
gel
oxibutinin
Prior art date
Application number
RU2005116678/15A
Other languages
English (en)
Other versions
RU2311170C2 (ru
Inventor
Стивен У. САНДЕРС (US)
Стивен У. САНДЕРС
Чарлз Д. ЭБЕРТ (US)
Чарлз Д. ЭБЕРТ
Original Assignee
Уотсон Фармасьютикалс, Инк. (Us)
Уотсон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2005116678(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уотсон Фармасьютикалс, Инк. (Us), Уотсон Фармасьютикалс, Инк. filed Critical Уотсон Фармасьютикалс, Инк. (Us)
Publication of RU2005116678A publication Critical patent/RU2005116678A/ru
Application granted granted Critical
Publication of RU2311170C2 publication Critical patent/RU2311170C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00646—Medication patches, e.g. transcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (19)

1. Гелевый препарат оксибутинина для местного применения, содержащий терапевтически эффективное количество оксибутинина и гель-носитель, причем препарат имеет рН приблизительно от 4 до приблизительно 11 и оксибутинин присутствует в виде свободного основания оксибутинина, фармацевтически приемлемой соли оксибутинина или их смеси и препарат получают в виде непоглощенной формы для местного нанесения на поверхность кожи.
2. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно от 4 до приблизительно 11.
3. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно от 5 до приблизительно 11.
4. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно от 6 до приблизительно 11.
5. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно от 4 до приблизительно 10.
6. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно от 5 до приблизительно 10.
7. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно от 6 до приблизительно 10.
8. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно 6.
9. Гелевый препарат оксибутинина по п.1, где препарат имеет рН приблизительно 9.
10. Гелевый препарат оксибутинина по п.1, где оксибутинин представляет собой свободное основание оксибутинина.
11. Гелевый препарат оксибутинина по п.1, где оксибутинин представляет собой хлорид оксибутинина.
12. Гелевый препарат оксибутинина по п.1, где оксибутинин представляет собой комбинацию свободного основания оксибутинина и хлорида оксибутинина.
13. Гелевый препарат оксибутинина для местного введения, содержащий терапевтически эффективное количество оксибутинина в геле-носителе, которое при местном введении в непоглощенной форме является достаточным для обеспечения скорости проникновения оксибутинина через кожу по меньшей мере приблизительно 10 мкг/см2 на протяжении периода по меньшей мере приблизительно 24 ч.
14. Гелевый препарат оксибутинина по п.13, где скорость проникновения оксибутинина через кожу составляет по меньшей мере приблизительно 20 мкг/см2 на протяжении периода по меньшей мере приблизительно 24 ч.
15. Гелевый препарат оксибутинина по п.13, где препарат имеет значение рН, которое повышает проникновение оксибутинина через кожу при непоглощенном местном введении препарата.
16. Гелевый препарат оксибутинина по п.13, где препарат включает в себя усилитель проникновения.
17. Гелевый препарат оксибутинина по п.13, где оксибутинин представляет собой свободное основание оксибутинина.
18. Гелевый препарат оксибутинина по п.13, где оксибутинин представляет собой хлорид оксибутинина.
19. Гелевый препарат оксибутинина по п.13, где оксибутинин представляет собой смесь свободного основания оксибутинина и хлорида оксибутинина.
RU2005116678/15A 2002-11-01 2003-10-31 Композиции оксибутинина и способы чрескожной терапии оксибутинином RU2311170C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/286,381 US7029694B2 (en) 2000-04-26 2002-11-01 Compositions and methods for transdermal oxybutynin therapy
US10/286,381 2002-11-01

Publications (2)

Publication Number Publication Date
RU2005116678A true RU2005116678A (ru) 2005-12-10
RU2311170C2 RU2311170C2 (ru) 2007-11-27

Family

ID=32312070

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005116678/15A RU2311170C2 (ru) 2002-11-01 2003-10-31 Композиции оксибутинина и способы чрескожной терапии оксибутинином

Country Status (16)

Country Link
US (1) US7029694B2 (ru)
EP (4) EP3659562A1 (ru)
JP (4) JP2006513161A (ru)
KR (4) KR20050061588A (ru)
CN (2) CN101904812A (ru)
AU (2) AU2003287377B2 (ru)
BR (1) BR0315867A (ru)
CA (2) CA2718277C (ru)
DK (1) DK1565136T3 (ru)
ES (2) ES2532495T3 (ru)
MX (1) MXPA05004110A (ru)
NO (2) NO339626B1 (ru)
NZ (2) NZ539562A (ru)
RU (1) RU2311170C2 (ru)
WO (1) WO2004041188A2 (ru)
ZA (1) ZA200503316B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE60143360D1 (de) * 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
WO2004024187A2 (en) * 2002-09-13 2004-03-25 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
EP1622576B1 (en) * 2003-05-07 2007-04-25 Firmenich Sa Sprayable perfume with an improved tenacity
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
TW200512013A (en) * 2003-09-18 2005-04-01 Orient Europharma Co Ltd Gel formulation of oxybutynin hydrochloride
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2009150408A2 (en) * 2008-06-13 2009-12-17 Summit Corporation Plc Topical antimuscarinic formulations
CA2730847A1 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CN101564377A (zh) * 2009-04-24 2009-10-28 杭州锐思医药科技有限公司 奥昔布宁透皮凝胶及其制备方法
US8920392B2 (en) * 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
EP2473161B1 (en) 2009-08-31 2017-05-17 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
CN102309447A (zh) * 2010-07-06 2012-01-11 上海现代药物制剂工程研究中心有限公司 含盐酸奥昔布宁的自粘性喷雾透皮组合物及制备方法
US11083696B2 (en) * 2011-09-21 2021-08-10 University College Cardiff Consultants Limited Dispersion anaesthetic device
EP2772252B1 (en) * 2011-10-26 2020-03-18 Hisamitsu Pharmaceutical Co., Inc. Oxybutynin-containing transdermal absorption preparation
ES2677474T3 (es) 2012-03-14 2018-08-02 Vanda Pharmaceuticals Inc. Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos
CN102614108B (zh) * 2012-04-16 2013-10-16 上海现代药物制剂工程研究中心有限公司 含奥昔布宁的立方水质液晶凝胶经皮吸收制剂及其制法
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
EP4122460A1 (en) 2015-01-09 2023-01-25 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
ES2861052T3 (es) * 2015-04-30 2021-10-05 Hisamitsu Pharmaceutical Co Composición tópica que comprende oxibutinina para el tratamiento de la hiperhidrosis
CN108495654B (zh) * 2016-02-25 2022-10-25 久光制药株式会社 外用液剂
WO2018063876A1 (en) * 2016-09-30 2018-04-05 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery systems comprising cetirizine dihydrochloride
US11033511B2 (en) * 2017-08-01 2021-06-15 Hisamitsu Pharmaceutical Co., Inc. Pharmaceutical patch
WO2022045200A1 (ja) * 2020-08-28 2022-03-03 久光製薬株式会社 多汗症治療用の外用液剤

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US161044A (en) * 1875-03-23 Improvement in combined shovels and ash-pan lifters
US147236A (en) * 1874-02-10 Improvement in devices for riveting the teeth of saws
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
JPS6025045B2 (ja) 1980-03-19 1985-06-15 製鉄化学工業株式会社 塩水吸収能のすぐれたアクリル酸重合体の製造方法
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5028430A (en) 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
EP0481007B1 (en) 1989-06-07 1997-01-22 BAZZANO, Gail S SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
US5922342A (en) 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
EP0767659B1 (en) 1992-05-13 1999-10-20 Alza Corporation Transdermal administration of oxybutynin
US5900250A (en) 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
DE69420419T2 (de) 1993-09-29 1999-12-23 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
WO1995024172A1 (en) 1994-03-07 1995-09-14 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
NL9401051A (nl) * 1994-06-24 1996-02-01 Stichting Tech Wetenschapp Microfoon op basis van fluidum-stroommeting en akoestische generator gebaseerd daarop.
US5840338A (en) 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
DE69524614T2 (de) 1994-10-05 2002-09-12 Hisamitsu Pharmaceutical Co Arzneimittelbestandteile einschliesslich eines n-substituierten o-toluidinderivats und transdermal absorbierbare zubereitung
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5582838A (en) 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5532278A (en) 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
DE19511698C1 (de) 1995-03-30 1996-08-22 Schober Werkzeug & Maschbau Vorrichtung zum Verbinden einer Siegelfolie mit einer Materialbahn
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
EP1238659B1 (en) 1996-02-02 2004-09-29 ALZA Corporation Sustained delivery of an active agent using an implantable system
JPH09255565A (ja) * 1996-03-26 1997-09-30 Daikyo Yakuhin Kogyo Kk 皮膚局所麻酔用ヒドロゲルパッチ
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998018416A1 (en) 1996-10-30 1998-05-07 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
ATE333266T1 (de) 1997-03-31 2006-08-15 Alza Corp Diffusionsgesteuertes implantierbares verabreichungssystem
DE19882286T1 (de) 1997-04-03 2000-04-27 Point Biomedical Corp Intravesikale Medikamentenabgabesysteme
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
US5905391A (en) 1997-07-14 1999-05-18 Intel Corporation Master-slave delay locked loop for accurate delay or non-periodic signals
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DK1510213T3 (da) 1997-11-10 2009-03-23 Strakan Int Ltd Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron
DE29823343U1 (de) * 1998-03-20 1999-07-15 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
AR018321A1 (es) 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
FR2779438B1 (fr) 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
AU773778B2 (en) * 1999-09-08 2004-06-03 Watson Pharmaceuticals, Inc. Using quaternary ammonium salts for transdermal drug delivery
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
WO2001080796A1 (en) * 2000-04-26 2001-11-01 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
JP5039252B2 (ja) * 2000-08-31 2012-10-03 ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー 性機能低下を治療するための医薬組成物及び方法
US9875202B2 (en) 2015-03-09 2018-01-23 Nordic Semiconductor Asa Peripheral communication system with shortcut path

Also Published As

Publication number Publication date
US20030147926A1 (en) 2003-08-07
CA2718277A1 (en) 2004-05-21
EP2612629A1 (en) 2013-07-10
KR20050061588A (ko) 2005-06-22
KR20110043725A (ko) 2011-04-27
MXPA05004110A (es) 2005-06-22
ZA200503316B (en) 2006-08-30
AU2010200418B2 (en) 2012-06-14
AU2003287377B2 (en) 2010-02-25
EP2606865A1 (en) 2013-06-26
BR0315867A (pt) 2005-09-27
AU2003287377A1 (en) 2004-06-07
JP2017031191A (ja) 2017-02-09
DK1565136T3 (da) 2015-04-20
EP1565136A4 (en) 2010-12-22
ES2532495T3 (es) 2015-03-27
EP2612629B1 (en) 2019-12-04
EP1565136B1 (en) 2015-02-25
JP6118358B2 (ja) 2017-04-19
US7029694B2 (en) 2006-04-18
EP1565136A2 (en) 2005-08-24
CN101904812A (zh) 2010-12-08
JP2015131826A (ja) 2015-07-23
JP6209263B2 (ja) 2017-10-04
NO343756B1 (no) 2019-06-03
CA2504021C (en) 2013-08-13
NZ539562A (en) 2008-11-28
AU2010200418A1 (en) 2010-02-25
KR20130026510A (ko) 2013-03-13
EP3659562A1 (en) 2020-06-03
WO2004041188A2 (en) 2004-05-21
NO339626B1 (no) 2017-01-16
RU2311170C2 (ru) 2007-11-27
KR20120038026A (ko) 2012-04-20
ES2764081T3 (es) 2020-06-02
WO2004041188A3 (en) 2004-10-28
NO20161918A1 (no) 2005-05-31
CA2718277C (en) 2015-02-03
NO20052625L (no) 2005-05-31
CN1708269A (zh) 2005-12-14
CA2504021A1 (en) 2004-05-21
JP2006513161A (ja) 2006-04-20
JP5770582B2 (ja) 2015-08-26
JP2012046526A (ja) 2012-03-08
NZ586108A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
RU2005116678A (ru) Композиции оксибутинина и способы чрескожной терапии оксибутинином
KR100764156B1 (ko) 국소 마취제의 국소 투여를 위한 피내 침투제
JP3526887B2 (ja) 消炎鎮痛外用貼付剤
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
CA2201784A1 (en) Method and formulation of stimulating nitric oxide synthesis
CA2274074A1 (en) Novel compounds with analgesic effect
ES463877A1 (es) Procedimiento para la preparacion de benzamidas y naftamidasn-(2-aminocicloalifaticas).
NZ505809A (en) (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and its salts and pharmaceuticals thereof; useful as medicaments
JP2002521428A5 (ru)
EP1623985A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents
IL152770A (en) Use of Gabapentin analogues for the preparation of preparations for the treatment of sleep disorders
JPH06104624B2 (ja) 経皮吸収剤
RU2004106779A (ru) Способ профилактики и/или лечения дисфункции и/или нарушения структуры ногтей, пластырь для его осуществления и его применение
RU2001111868A (ru) Антагонисты метаботропных глутаматных рецепторов (mglur5) для лечения боли и состояния тревоги
WO2003073981A3 (en) Novel of cytokine inhibitors
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
SE0102440D0 (sv) New compound
WO2004105690A3 (en) Treatment of chronic pain associated with drug or radiation therapy
RU2001111808A (ru) Фармацевтическая композиция, содержащая сочетание правовращающего и левовращающего изомеров соталола
JP2002537232A5 (ru)
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
SE9900190D0 (sv) New compounds
RU99100703A (ru) Модифицированная форма гидрохлорида r(-)-n -(4,4-ди(3-метил-тиен-2-ил)бут-3- енил)-нипекотиновой кислоты

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20141101